ImmunoPrecise Antibodies shares up as it launches new antibody discovery platform with US pharma group
Shares in ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) were higher on Tuesday as the group said it had launched a “powerful and unique” platform for therapeutic antibody discovery with a US pharma firm.
It expands the group’s offerings and the technology allows the selection of rare, fully human antibodies using what’s called DeepDisplay, which is a combination of transgenic animal immunization and custom antibody selections, the company said.
READ: ImmunoPrecise Antibodies sees 56% increase in 3Q revenue as it continues to advance business
“The ability to select needle-in-the-haystack antibodies using this powerful combination of OmniAb rodent (mouse or rat) immunization and phage display antibody selections provide an entirely new avenue in therapeutic antibody discovery,” said Debby Kruijsen, the general manager of the firm’s ModiQuest Research subsidiary.
CEO of ImmunoPrecise Jennifer Bath added: “With over 15 years of experience in customized and precision-based phage display, IPA has coupled this powerful technology with Ligand‘s OmniAb transgenic rodent platforms to enable the accelerated discovery of highly diverse, fully human antibodies with superior clinical safety and efficacy and the lowest immunogenicity.”
The company added that data generated during the large pharma and OmniAb collaboration will be publicly presented at conferences in Munich and Boston in March and May respectively as well as via live webinar.
Last week, the antibody discovery firm told investors it had increased revenue and gross margins in the third quarter, as it continues to grow the core business.
Global antibody services
The British Columbia-headquartered company provides global antibody services ranging from target analysis to pre-clinical studies.
The group’s acquisitions of Netherlands-based U-Protein and ModiQuest had helped boost revenue in the quarter to end-January to around $2.69 million, it said, compared to the same period in 2018.
Gross margin rose 58% to around $1.57 million from $989,203 in 2018, it added, mainly due to the group focusing on higher margin projects at its new B-cell lab in Victoria, British Columbia and further operational efficiencies put into its operations.
Shares in Toronto added around 4% on Monday at $0.75.
Contact Giles at [email protected]
Follow him on Twitter@Gile74
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/217789/immunoprecise-antibodies-shares-up-as-it-launches-new-antibody-discovery-platform-with-us-pharma-group-217789.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).